Uni-Bio Science Group achieves key milestones with a new collagen dressing approval and a skincare product launch.

Uni-Bio Science Group has achieved two major milestones in the medical aesthetics market. The company received approval for its recombinant collagen dressing as a Class II medical device and launched "肌顏態®," a new medical aesthetics product. These innovations, which aim to enhance skin quality and repair, have garnered attention from dermatologists and reflect the company's commitment to innovation and market growth. The medical aesthetics market is projected to be worth over RMB 600 billion by 2030.

December 02, 2024
4 Articles